Literature DB >> 7922559

Transglutaminase facilitates the formation of polymers of the beta-amyloid peptide.

S M Dudek1, G V Johnson.   

Abstract

One of the major pathological characteristics of Alzheimer's disease is the increased number of amyloid-containing senile plaques within the brain. The dense cores of these plaques are composed primarily of highly insoluble aggregates of a 39-43-residue peptide referred to as the beta-amyloid peptide (beta A). The mechanisms by which these insoluble extracellular deposits of beta A are formed remain unknown. In this study, the cross-linking of beta A by the calcium-dependent enzyme, transglutaminase was examined. Transglutaminases are a family of enzymes which are found in brain, and catalyse the cross-linking of specific proteins into insoluble polymers. Synthetic beta A (1-40) was readily cross-linked by transglutaminase, forming multimers in a time-dependent fashion. Furthermore, a second peptide with a substitution similar to that in the Dutch-type hereditary amyloidosis mutation (Glu22 to Gln) was also found to be a substrate for transglutaminase. Since transglutaminase covalently cross-links proteins through glutamine residues, it is suggested that transglutaminase contributes to amyloid deposition in Dutch-type hereditary amyloidosis, and possibly Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7922559     DOI: 10.1016/0006-8993(94)90688-2

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  31 in total

1.  [Cross-linking in an artificial human cornea via induction of tissue transglutaminases].

Authors:  N Kopsachilis; I Tsinopoulos; K T Tsaousis; R Meiller; S A Dimitrakos; F E Kruse; U W Luessen
Journal:  Ophthalmologe       Date:  2012-06       Impact factor: 1.059

2.  Transglutaminase 1 and its regulator tazarotene-induced gene 3 localize to neuronal tau inclusions in tauopathies.

Authors:  Micha M M Wilhelmus; Mieke de Jager; Annemieke J M Rozemuller; John Brevé; John G J M Bol; Richard L Eckert; Benjamin Drukarch
Journal:  J Pathol       Date:  2011-10-18       Impact factor: 7.996

3.  Effects of tissue transglutaminase on beta -amyloid1-42-induced apoptosis.

Authors:  Joseph J Wakshlag; Marc A Antonyak; Jason E Boehm; Karen Boehm; Richard A Cerione
Journal:  Protein J       Date:  2006-01       Impact factor: 2.371

4.  Iron enhances the neurotoxicity of amyloid β.

Authors:  Lin Wang; Guohua Xi; Richard F Keep; Ya Hua
Journal:  Transl Stroke Res       Date:  2011-07-29       Impact factor: 6.829

Review 5.  The toxicity in vitro of beta-amyloid protein.

Authors:  L L Iversen; R J Mortishire-Smith; S J Pollack; M S Shearman
Journal:  Biochem J       Date:  1995-10-01       Impact factor: 3.857

6.  The Aggregation Paths and Products of Aβ42 Dimers Are Distinct from Those of the Aβ42 Monomer.

Authors:  Tiernan T O'Malley; William M Witbold; Sara Linse; Dominic M Walsh
Journal:  Biochemistry       Date:  2016-10-26       Impact factor: 3.162

7.  Residues in the synuclein consensus motif of the alpha-synuclein fragment, NAC, participate in transglutaminase-catalysed cross-linking to Alzheimer-disease amyloid beta A4 peptide.

Authors:  P H Jensen; E S Sørensen; T E Petersen; J Gliemann; L K Rasmussen
Journal:  Biochem J       Date:  1995-08-15       Impact factor: 3.857

8.  Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies.

Authors:  Eunsung Junn; Ruben D Ronchetti; Martha M Quezado; Soo-Youl Kim; M Maral Mouradian
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-07       Impact factor: 11.205

9.  Tissue transglutaminase, protein cross-linking and Alzheimer's disease: review and views.

Authors:  Deng-Shun Wang; Dennis W Dickson; James S Malter
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

Review 10.  Transglutaminases and neurodegeneration.

Authors:  Thomas M Jeitner; John T Pinto; Boris F Krasnikov; Mark Horswill; Arthur J L Cooper
Journal:  J Neurochem       Date:  2009-05       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.